Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to extend life in tough pancreatic cancer

NCT ID NCT06361888

Disease control Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This trial tests whether adding two drugs (surufatinib and camrelizumab) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 502 adults who have not had prior treatment for their advanced cancer will be randomly assigned to the new combo or standard chemo alone. The main goal is to see if the combo improves overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 502 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Fully understand and voluntarily sign an informed consent form, willing and able to follow the study process; 2. Age range is 18-75 years old (inclusive); 3. Pancreatic cancer confirmed by histology or cytology; 4. Stage IV metastasis Pancreatic cancer patients; 5. Have not received previous systematic first line anti-tumor treatment in the stage of metastatic pancreatic cancer; 6. According to RECIST 1.1, there is at least one measurable lesion; 7. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1; 8. Expected survival time ≥ 12 weeks; Exclusion Criteria: 1. Use of systematic non-specific immunomodulatory therapy within 2weeks prior to the first dose； 2. Presence of other malignancies in the past 5 years; 3. Received major surgical surgery within 4 weeks before the first dose; 4. Received palliative radiotherapy within 1 week before the first dose; received radical radiotherapy within 4 weeks before the first dose; 5. Any known allergy to surufatinib or its components, camrelizumab, nab-paclitaxel, or gemcitabine; 6. Received strong-inducers or strong-inhibitors of cytochrome P450 (CYP) 3A within 2 weeks or 5 half-lives (whichever is longer) before the first dose; 7. Use of immunosuppressive drugs within 4 weeks before first dose; 8. Known history of clinically significant liver disease, including active viral hepatitis infection or other active hepatitis or clinically significant moderate to severe cirrhosis; 9. Patients who currently have hypertension that cannot be controlled by medication;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    52 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital Of Jining Medical University

    RECRUITING

    Jining, Shandong, China

  • Anhui Provincial Hospital

    RECRUITING

    Hefei, Anhui, China

  • Anyang Cancer Hospital

    RECRUITING

    Anyang, Henan, China

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

    RECRUITING

    Shenzhen, Guangdong, China

  • Chongqing General Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, China

  • Chongqing University Cancer Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, China

  • First Hospital of Qinhuangdao

    RECRUITING

    Qinhuangdao, Hebei, China

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, China

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guandong, Guangzhou, China

  • Hainan General Hospital

    RECRUITING

    Haikou, Hainan, China

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, China

  • Huashan Hospital, Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Hubei Cancer Hospital

    RECRUITING

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, China

  • Jiangsu Cancer Hospital

    RECRUITING

    Nanjing, Jiangsu, China

  • Jiangxi Cancer Hospital

    RECRUITING

    Nanchang, Jiangxi, China

  • Jiangyin People's Hospital

    RECRUITING

    Wuxi, Jiangsu, China

  • Jilin Cancer Hospital

    RECRUITING

    Changchun, Jilin, China

  • Liaoning Cancer Hospital

    RECRUITING

    Shenyang, Liaoning, China

  • Linyi People's Hospital

    RECRUITING

    Linyi, Shandong, China

  • Nanjing Drum Tower Hospital

    RECRUITING

    Nanjing, Jiangsu, China

  • Nanjing Tianyinshan Hospital

    RECRUITING

    Nanjing, Jiangsu, China

  • Nantong Cancer Hospital

    RECRUITING

    Nantong, Jiangsu, China

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Shandong Cancer Hospital

    RECRUITING

    Jinan, Shandong, China

  • Shanxi Provincial Cancer Hospitial

    RECRUITING

    Taiyuan, Shanxi, China

  • Sichuan Cancer Hospital

    RECRUITING

    Chengdu, Sichuan, China

  • The First Affiliated Hospital of Guangxi Medical University

    RECRUITING

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Henan Medical University

    RECRUITING

    Xinxiang, Henan, China

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi’an, Shanxi, China

  • The First Affiliated Hospital of Xiamen University

    RECRUITING

    Xiamen, Fujian, China

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, China

  • The First Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

  • Tianjin Cancer Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, China

  • Tianjin Cancer Hospital Airport Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, China

  • XiangYa Hospital CentralSouth University

    RECRUITING

    Changsha, Hunan, China

  • Yunnan Cancer Hospital

    RECRUITING

    Kunming, Yunnan, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

  • Zhejiang Provincial People's Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

  • ZhongShan Hospital Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.